23.05 -0.05 (-0.20%)
After hours: 4:26PM EDT
|Bid||23.09 x 900|
|Ask||23.10 x 1800|
|Day's Range||22.79 - 23.34|
|52 Week Range||17.20 - 28.45|
|Beta (3Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.
Pershing Square Capital’s Bill Ackman has had a roller-coaster of success and failures in recent years. Perhaps no failure has been as highly publicized as his stake in Valeant Pharmaceuticals, which is now Bausch Health Companies Inc (NYSE: BHC). Ackman reportedly first took his massive stake in Valeant back in 2015 at an average price of around $196 per share.
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.
Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
Bausch Health Companies Inc. said Tuesday it will pay down an additional $100 million worth of debt this week, which will eliminate all mandatory amortization for the first quarter of 2020. The stock rose 1.9% in premarket trading. The maker of pharmaceutical, medical-device and over-the-counter products said it will use cash generated from operations to pay down the senior secured terms loans. The stock has lost 1.6% over the past three months but has rallied 28.6% year to date through Monday, while the S&P 500 has gained 17.5% this year.
It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * This Analyst Doesn't See a Comeback in Netflix (NFLX) Stock Any Time Soon * There's Light at the End of the Tunnel for Canopy Growth (CGC) Stock, Analyst Says * Aurora Cannabis (ACB) Wins a 'Buy' for Rolling Up the Marijuana Industry * Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet
Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BHC totaled $1.20 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BHC credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.